Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.
Microtubule stabilizing agents (MSAs) comprise a class of drugs that bind to microtubule (MT) polymers and stabilize them against disassembly. Several of these agents are currently in clinical use as anticancer drugs, whereas others are in various stages of development. Nonetheless, there is insufficient knowledge about the molecular modes of their action. Recent studies from our laboratory utilizing hydrogen-deuterium exchange in combination with mass spectrometry (MS) provide new information on the conformational effects of Taxol and discodermolide on microtubules isolated from chicken erythrocytes (CET). We report here a comprehensive analysis of the effects of epothilone B, ixabepilone (IXEMPRA(TM)), laulimalide, and peloruside A on CET conformation. The results of our comparative hydrogen-deuterium exchange MS studies indicate that all MSAs have significant conformational effects on the C-terminal H12 helix of α-tubulin, which is a likely molecular mechanism for the previously observed modulations of MT interactions with microtubule-associated and motor proteins. More importantly, the major mode of MT stabilization by MSAs is the tightening of the longitudinal interactions between two adjacent αβ-tubulin heterodimers at the interdimer interface. In contrast to previous observations reported with bovine brain tubulin, the lateral interactions between the adjacent protofilaments in CET are particularly strongly stabilized by peloruside A and laulimalide, drugs that bind outside the taxane site. This not only highlights the significance of tubulin isotype composition in modulating drug effects on MT conformation and stability but also provides a potential explanation for the synergy observed when combinations of taxane and alternative site binding drugs are used.
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Marina
M
Khrapunovich-Baine
Vilas
V
Menon
Chia-Ping Huang
CP
Yang
Peter T
PT
Northcote
John H
JH
Miller
Ruth Hogue
RH
Angeletti
Andras
A
Fiser
Susan Band
SB
Horwitz
Hui
H
Xiao
D000818:Animals; D001665:Binding Sites; D001921:Brain; D001923:Brain Chemistry; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry*; D002417:Cattle; D034261:Epothilones / Q000737:chemistry*; D007783:Lactones / Q000737:chemistry*; D018942:Macrolides / Q000737:chemistry*; D013058:Mass Spectrometry; D008870:Microtubules / Q000737:chemistry*; D009419:Nerve Tissue Proteins / Q000737:chemistry*; D017433:Protein Structure, Secondary; D014404:Tubulin / Q000737:chemistry*; D050257:Tubulin Modulators / Q000737:chemistry*
D019086:Bridged Bicyclo Compounds, Heterocyclic; D034261:Epothilones; D007783:Lactones; D018942:Macrolides; D009419:Nerve Tissue Proteins; D014404:Tubulin; D050257:Tubulin Modulators; C117305:laulimalide; C414085:peloruside A; C430592:ixabepilone; C093788:epothilone B
Cell Motil Cytoskeleton. 2003 Jun;55(2):77-96
12740870
Annu Rev Med. 1997;48:353-74
9046968
J Mol Biol. 2008 May 16;378(5):1016-30
18405918
J Biol Chem. 1983 Jul 10;258(13):8357-64
6863292
Mol Biol Cell. 1992 Oct;3(10):1155-67
1421572
Biochemistry. 1997 Mar 25;36(12):3554-62
9132006
Biochemistry. 2002 Jul 23;41(29):9109-15
12119025
Lancet Oncol. 2008 Feb;9(2):168-75
18237851
J Biol Chem. 1992 Mar 15;267(8):5625-30
1544937
Cell Struct Funct. 1993 Jun;18(3):173-82
7902216
Cancer Res. 2004 Aug 1;64(15):5063-7
15289305
Nature. 1998 Jan 8;391(6663):199-203
9428769
Science. 2004 Aug 6;305(5685):866-9
15297674
J Cell Biol. 2002 Jun 24;157(7):1187-96
12082079
Bioinformatics. 1999 Apr;15(4):327-32
10320401
J Org Chem. 2000 Jan 28;65(2):445-9
10813954
Mol Pharm. 2007 Mar-Apr;4(2):269-80
17397239
Chem Biol. 2005 Mar;12(3):339-48
15797218
J Mol Biol. 2001 Nov 9;313(5):1045-57
11700061
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10166-10173
16801540
Cell. 1999 Jan 8;96(1):79-88
9989499
Nat Rev Cancer. 2010 Mar;10(3):194-204
20147901
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6746-51
15096589
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11358-62
7972064
J Biol Chem. 1997 Jan 24;272(4):2534-41
8999970
Mol Biol Cell. 2001 Apr;12(4):971-80
11294900
Biochemistry. 2009 Dec 15;48(49):11664-77
19863156
Eur J Biochem. 1993 Nov 15;218(1):107-16
8243458
Biochemistry. 2002 Mar 26;41(12):3870-4
11900528
Biochemistry. 2006 Oct 3;45(39):11762-75
17002277
J Biol Chem. 1997 Jul 4;272(27):17118-25
9202030
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9
10688884
Bioorg Med Chem Lett. 2004 Oct 4;14(19):4825-9
15341932
Curr Opin Struct Biol. 2006 Apr;16(2):221-9
16549346
Biochemistry. 2000 Jan 18;39(2):281-91
10630987
FEBS Lett. 2003 Mar 27;539(1-3):34-6
12650922
Cancer Res. 1995 Jun 1;55(11):2325-33
7757983
Oncogene. 2003 Oct 20;22(47):7280-95
14576838
J Biol Chem. 1994 Jan 21;269(3):2041-7
8294455
Biochemistry. 2009 Jun 9;48(22):4858-70
19388626
Nat Struct Biol. 1998 Jun;5(6):451-8
9628483
J Biol Chem. 1990 Jan 25;265(3):1794-9
2404018
J Med Chem. 2009 Nov 26;52(22):7328-32
19877653
Mol Pharmacol. 2006 Nov;70(5):1555-64
16887932
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10006-11
15226503
EMBO J. 2004 Jul 7;23(13):2459-67
15175652
J Cell Physiol. 2009 Dec;221(3):505-13
19650075
Histopathology. 2007 Oct;51(4):539-46
17714470
Mol Pharmacol. 2004 Jul;66(1):113-21
15213302
EMBO J. 2006 Dec 13;25(24):5932-41
17124495
EMBO J. 2010 Apr 7;29(7):1167-75
20224548
Mol Pharm. 2006 Jul-Aug;3(4):457-67
16889440